How South Carolina Became the Southeast's Fastest Growing Biotech Hub
Manufacturers keep choosing South Carolina to expand, drawn by talent, a business-friendly climate and quality of life.
The positive effects of membership.
As one of the fastest-growing industries in our state, SCbio champions life science professionals to build the bonds of a strong community for networking, funding, services and growth.
PROFESSIONAL DEVELOPMENT
PROFESSIONAL DEVELOPMENT
BUILDING THE FUTURE OF BIO
BUILDING THE FUTURE OF BIO
EXCLUSIVE ACCESS
EXCLUSIVE ACCESS
INDUSTRY VISIBILITY
INDUSTRY VISIBILITY
COLLABORATIVE ECOSYSTEM
COLLABORATIVE ECOSYSTEM
HUMAN IMPACT
HUMAN IMPACT
The positive effects of membership.







Build the life—and the science—that propels the future.
Start-Ups
Find mentors, talent and resources. SCbio makes those important connections easier.
Service Providers
Corporations
Students
Simply put, we’re here to make life sciences better.
Life science is blooming in South Carolina. We’re a national leader with cutting-edge discoveries, and SCbio wants the world to know. We represent more than 1,000 organizations to promote improvements in healthcare for a better tomorrow for everyone.
The future of science.
From advanced biomanufacturing to cutting-edge health specializations in oncology and neuroscience to leading solutions in digital health and health data, South Carolina is boldly shaping the future of science and the possibilities of life.
Breaking news and updates.
Our world-class life sciences ecosystem is blazing new trails in the life sciences. There’s always something happening.
- Uncategorized
Pharmaceutical and Consumer Health Products Leader of PL Developments Joins SCbio Strategic Advisory Board
SCbio is pleased to welcome Sean Dunn, site lead and general manager of PL Developments’ Piedmont, South Carolina, manufacturing facility, to its Strategic Advisory Board, bringing extensive experience in regulated manufacturing, operational leadership and business growth.
Since joining PL Developments in 2020, Dunn has overseen site operations spanning production, supply chain, quality and compliance. He leads the facility’s manufacturing of store-brand and name-brand over-the-counter pharmaceutical and consumer healthcare products in accordance with FDA regulations.
Under Dunn’s leadership, PL Developments has completed several multimillion-dollar expansion projects, growing its South Carolina workforce to more than 600 employees across over 1 million square feet of manufacturing and operational space in the Upstate.
A Lean Six Sigma-trained leader, Dunn applies continuous improvement principles throughout site operations, focusing on building resilient systems, improving efficiency and reducing waste.
Before joining PL Developments, Dunn founded and operated a luxury residential custom-building corporation in 2007. He led the business for 13 years before selling it in 2020 and pursuing his career in pharmaceutical manufacturing.
His experience leading large-scale operations, managing business growth and overseeing regulated manufacturing brings a valuable industry perspective to SCbio’s Strategic Advisory Board.
About SCbio
SCbio is the definitive, unifying leader in South Carolina’s life sciences sector, fostering authentic collaboration and innovation across academia, startups, government and established enterprises. As a member-driven economic development organization, SCbio represents an industry that generates $20.1 billion in annual economic impact and supports 63,000 jobs across South Carolina. Our members are unified by a mission to positively impact humanity through science across the ecosystem of advanced and specialty manufacturing; digital health and the data frontier; and cutting-edge health specializations. For additional information about SCbio and the life sciences industry, or to become a member, visit SCbio.org.
- Uncategorized
What One SCbio Breakfast Made Possible for Health Evolve Technologies
Building a life sciences company is difficult under the best of circumstances. Case in point: approximately 90% of biotech startups fail, with 60% failing within the first five years, according to David H. Crean, Ph.D., MBA, co-founder of CEO360 and managing partner at Cardiff Advisory, a boutique investment banking and strategic advisory firm serving life sciences and healthcare companies.
For women founders, access to capital presents an additional challenge. Across the broader technology sector, Stanford University research suggests all-women founding teams receive only 4% of venture capital funding, while Black women founders receive less than 1%. Kim Smith, founder and CEO of Health Evolve Technologies, knows how demanding that journey can be. Health Evolve is working to transform maternal health by helping women manage chronic disease before, during and after pregnancy. Its digital platform extends care beyond the clinic, combining remote monitoring, personalized education, AI-driven engagement and coordinated clinical support into one continuous experience. By supporting women throughout their reproductive years, the company aims to help address health risks before they become serious complications.

But for Smith, the challenges of building Health Evolve are also deeply personal.
The Challenges Behind Building Health Evolve
“Like many female founders, I’ve learned that raising capital often requires proving more with less,” said Smith. “Investors frequently ask women about risk while asking others about opportunity. That reality has pushed me to become even more disciplined, data-driven, and resilient.”
But for Smith, Health Evolve represents more than a mission. It reflects a journey rooted in personal experience.
She lost her first daughter, Lauren, to HELLP syndrome, a rare, life-threatening pregnancy complication involving the breakdown of red blood cells, elevated liver enzymes and low platelet counts. Often associated with severe preeclampsia, HELLP syndrome can develop during pregnancy or shortly after delivery.
That loss became the driving force behind Smith’s work. Lauren is the name of Health Evolve’s digital platform and a lasting reminder of the daughter who inspired her mission to help other women and families avoid experiencing a similar loss.
Through her own experience, Smith recognized the importance of a health care system that identifies and addresses serious complications before they become life-threatening. So, she set out to help change that by building a company focused on supporting women’s health earlier and more consistently, rather than waiting for complications to arise.
But translating that vision into a viable business requires navigating the same funding barriers, limited resources and industry challenges facing other life sciences founders.
That’s where SCbio has played an important role. From facilitating a connection that led to a clinical research opportunity to helping Health Evolve expand its professional network and visibility, the organization has supported the company at critical points in its growth.
Three Ways SCbio Helped Smith Health Evolve Grow Its Impact
Through SCbio, Smith has gained access to resources, relationships and connections that can help her move Health Evolve forward.
#1. An SCbio Introduction Led to Clinical Validation for Health Evolve
Shortly after joining SCbio, Smith received a nudge from SCbio’s Director of Member Relations and Engagement, Carla Whitlock, to attend her first SCbio Women in Life Sciences Breakfast in Greenville. There, she heard from Marjorie Jenkins from the University of South Carolina School of Medicine Greenville, which led to a follow-up meeting and an opportunity to present Health Evolve’s technology to the OB/GYN Department faculty at Prisma Health.
That initial connection helped pave the way for an IRB-approved clinical validation study with one of South Carolina’s leading health care systems.
“I remember just signing up as a member of SCbio the day before and receiving that gentle nudge to come to the breakfast,” said Smith. “That nudge from Carla Whitlock transformed our business beyond anything I could have imagined.”

#2. Building a Network of Peers and Industry Partners
Beyond the initial introduction to Prisma Health, SCbio has helped Smith build relationships and lasting connections.
Through SCbio’s networking events and educational programming, Health Evolve has expanded its network of peers across South Carolina’s life sciences community, including entrepreneurs, researchers, health systems, industry leaders and others who understand the challenges of growing a life sciences company.
“One of the greatest benefits of SCbio has been becoming part of a collaborative innovation community,” Smith shared. Whether it’s by attending an SCbio regional event, such as Breakfast and Bio, or South Carolina’s largest life sciences event, the Life + Science Conference, these opportunities lead to connections, business opportunities and help increase the awareness of Health Evolve’s technology.

#3. Bringing Health Evolve’s Mission to a Wider Audience
Those connections have also created opportunities for Smith to share her experience and introduce Health Evolve to a wider audience.
As a featured speaker at the Women in Life Sciences Breakfast and a panelist at SCbio’s annual Life + Science Conference, she has shared her perspective as a founder navigating the challenges of growing a healthcare company.
At the conference, Smith took the stage as a panelist, showcasing her brand to 400+ life sciences professionals. She also gained brand recognition from 30,000+ impressions generated by pre-conference promotional materials across SCbio’s communications channels.
At a Women in Life Sciences Breakfast, Smith served as the keynote speaker, connecting with more than 35 life sciences professionals, sharing insights from her experience, and introducing attendees to Health Evolve and the solutions it is bringing to the industry.

Health Evolve Plans for Lauren, New Partnerships and Expansion
Health Evolve is preparing to bring Lauren, its AI-powered women’s health platform, to market, with plans to deploy the technology alongside hospital and health system partners across South Carolina. By combining remote patient monitoring, personalized education, early risk identification and coordinated care, the goal is to help providers better manage chronic conditions that can contribute to poor maternal health outcomes.
The company is also expanding its community-based network across the Southeast and developing the Lauren Doula Network, a certification program that will equip doulas with training in chronic disease management, digital health and maternal health best practices. Together, Lauren’s technology and doula network aim to strengthen coordination between clinical teams and community providers, giving women more consistent support before, during and after pregnancy.
Health Evolve has also reached an important milestone, recently signing a two-year contract with the South Carolina Department of Public Health to support the CDC’s National Cardiovascular Health Program goals. The company is also preparing to raise its initial institutional round of capital to accelerate commercialization, expand health system partnerships and advance its technology.
Health Evolve is Building Solutions for Women’s Health in South Carolina and Across the Nation
Building an established life sciences company requires trusted relationships, access to industry expertise and opportunities to connect with the right people. And SCbio helped make those connections possible.
“One of the greatest benefits of SCbio has been becoming part of a collaborative innovation community,” said Smith. “Building a healthcare company can often feel isolating, but SCbio has created opportunities to engage with entrepreneurs, researchers, health systems, investors and industry leaders who genuinely want to see South Carolina succeed.”
Smith’s journey with SCbio began with an invitation to a Women in Life Sciences Breakfast that led to a clinical validation opportunity with Prisma Health. Through its programs, events and statewide networks, SCbio continues to help Health Evolve build relationships and gain visibility as it works to improve maternal health and scale its impact.
About Health Evolve
Health Evolve Technologies delivers tech-enabled chronic care management support for women of reproductive age – taking them on a journey from pre-pregnancy to early parenting. Their approach moves care from episodic visits into everyday life — identifying risk early, closing gaps in access and coordination, and delivering measurable improvements in clinical outcomes and total cost of care.
- Uncategorized
What’s Driving Life Sciences in 2026? Industry Experts Weigh In
The life sciences industry is entering a new phase of growth, and the factors influencing where companies invest, expand and manufacture are changing.
At NextGen Talks: Life Sciences, industry leaders gathered for a panel discussion titled Where We Stand: What’s Driving Life Sciences in 2026 to examine the forces shaping the industry and what they mean for communities competing for life sciences investment.
Moderated by Sarah Raehl, senior manager of location strategy at Deloitte Consulting, the discussion featured Seth Martindale of CBRE, Deb Boucher of Cushman & Wakefield, Matt Szuhaj of SDG and Boudewijn (Bo) Barth of GLS.

The panel explored everything from global investment trends and evolving site selection priorities to workforce needs, infrastructure and the growing role of artificial intelligence.
Here are four key takeaways from the conversation.
1. Life Sciences Companies Have Different Needs When Choosing a Location
One of the panel’s key points was that life sciences should not be treated as one industry with a universal set of needs.
A small research and development lab has very different requirements than a cell and gene therapy operation or a large-scale commercial manufacturing facility. Each requires different real estate, infrastructure, workforce capabilities and regulatory considerations.
The distinction is very important for communities hoping to attract new investment. A location that works well for a research operation may not have the utilities, workforce or available sites needed to support commercial manufacturing.
Panelists also challenged the assumption that life sciences manufacturing must be located near a major research university. While academic partnerships can support innovation, manufacturing operations have different priorities. Communities with established manufacturing workforces, reliable utilities and development-ready sites can be strong contenders, even without a major research institution nearby.

2. Site Readiness Is Becoming a Major Competitive Advantage
Incentives have long played a role in economic development, but the panel emphasized that companies are paying close attention to something else: how quickly a location can support their operations.
Construction costs have climbed, and lead times for essential building materials, including steel, can stretch nine to 14 months. A new commercial biomanufacturing facility can cost $100 million or more, making the financial and logistical risks of development significant.
For companies, having a site with the right infrastructure already in place can make a meaningful difference.
Reliable, consistent power is particularly important. Even a brief disruption can jeopardize an entire manufacturing campaign. Wastewater treatment capacity is another consideration, as companies may face $15 million to $20 million in additional costs if they must build their own treatment infrastructure.
Rather than investing heavily in speculative buildings, panelists encouraged economic development organizations to prepare sites with core utilities, permitting and infrastructure already addressed.
3. Workforce and Incentive Strategies Need to Keep Pace with Manufacturing
As life sciences manufacturing becomes more automated and capital-intensive, traditional economic development strategies may need to evolve.
Panelists noted that incentive programs focused exclusively on job creation do not always reflect the economic value of modern manufacturing facilities. Large investments can generate significant growth in the tax base and economic activity without producing the same number of direct jobs as more traditional manufacturing operations.
Custom incentives that help offset infrastructure and upfront capital costs may be more effective for attracting these projects.
Workforce development is another important piece of the equation. Many biomanufacturing technician positions do not require a four-year degree. Two-year associate degrees, industry certifications and targeted training can prepare workers for a range of roles.
South Carolina communities can also look to existing talent pools in food and beverage, consumer packaged goods and advanced manufacturing. Workers with experience in regulated production environments may already have many of the skills and workplace habits needed for biomanufacturing.
4. AI Will Influence the Industry, but Adoption Takes Time
Artificial intelligence is changing how companies approach research, drug discovery and genomics. However, panelists cautioned against expecting an immediate transformation across biomanufacturing operations.
The life sciences industry operates within a highly regulated environment. Changes to established production processes can require extensive review and, in some cases, full FDA re-licensing. That makes rapid adoption more complicated than in industries where new technologies can be implemented with fewer regulatory hurdles.
For now, AI’s most immediate influence is expected to remain concentrated in research and development, with broader manufacturing applications developing over time.
Future Opportunities for South Carolina
The discussion offered an important perspective for communities looking to compete for life sciences investment: opportunities are not limited to the country’s largest innovation hubs.
Mid-sized and emerging markets can attract companies by understanding the specific needs of different life sciences segments, preparing sites for development, investing in workforce training and maintaining the flexibility to support projects as they grow.
There is also an opportunity to look beyond major pharmaceutical companies. Contract development and manufacturing organizations (CDMOs), research partners, specialized logistics providers and packaging suppliers often follow larger manufacturing investments, creating additional opportunities for communities to build their life sciences presence.
As companies evaluate where to establish their next operations, the communities that understand these changing priorities will be better positioned to compete.
For South Carolina, that means continuing to build on its manufacturing strengths, workforce partnerships and growing life sciences ecosystem while preparing for the next wave of industry investment.
- Uncategorized
New Study Identifies Life Sciences Manufacturing Opportunities in Central South Carolina
COLUMBIA, S.C. – A new study commissioned by the Central SC Alliance (CSCA) identifies advanced manufacturing and supply chain development as Central South Carolina’s strongest near-term opportunities for attracting life sciences investment.
The study highlights the eight-county region’s established pharmaceutical manufacturing base, experienced workforce, research capabilities and proximity to major Southeastern life sciences markets as key competitive advantages.
“We see tremendous opportunity for Central South Carolina in life sciences, but we also want to be deliberate about where we can compete and win,” said Jason Giulietti, president and CEO of the CSCA. “This study gives us a clearer picture of the strengths already here and a roadmap for pursuing the next investment.”
Pharmaceutical manufacturers, including Ritedose and Nephron Pharmaceuticals, have established and expanded operations in the region, strengthening its capabilities in regulated pharmaceutical production, sterile manufacturing, packaging and distribution. Combined with Central South Carolina’s broader manufacturing and logistics expertise, these assets position the region to compete for additional life sciences investment.
The findings come as South Carolina’s life sciences industry continues to expand. According to the study, the sector generates an estimated $20.1 billion in annual economic impact, supports approximately 63,000 jobs statewide and is growing at four times the statewide average employment rate.
“South Carolina’s life sciences sector is growing because different regions bring different strengths to the table,” said James Chappell, president and CEO of SCbio. “Central South Carolina’s manufacturing base, research activity and health care and academic partners add important capabilities to a statewide ecosystem that continues to mature.”
The study also highlights Central South Carolina’s strategic location within the broader Southeastern life sciences corridor, including proximity to North Carolina’s Research Triangle. This positioning creates opportunities to attract companies seeking manufacturing capacity, expansion opportunities and supply chain support near established research and development centers.
“Companies making major location decisions gauge a region’s capacity to support them for the long term,” said Tushar Chikhliker, chair of the CSCA Board of Directors. “Central South Carolina combines manufacturing capability, access to talent and room to scale with proximity to established life sciences markets across the Southeast.”
Beyond manufacturing, the study identifies research, health care and workforce development as important contributors to the region’s long-term growth potential. The Midlands accounts for 30 percent of South Carolina’s National Institutes of Health funding, while the University of South Carolina, regional health systems and technical colleges provide research, commercialization, clinical and workforce development capabilities.
The study also identifies clinical and digital health as potential areas for future growth, supported by continued collaboration among academic institutions, health care providers and private industry.
“Life sciences growth depends on connecting research with talent, clinical partners and industry,” said Dr. Stephen Cutler, vice president for economic development and dean of the College of Pharmacy, University of South Carolina. “USC is an important part of that ecosystem, and we have an opportunity to build on those connections to advance innovation and support the sector’s growth across the region.”
The findings will help guide the Central SC Alliance’s business recruitment strategy and support regional efforts to attract new investment, strengthen industry partnerships and expand Central South Carolina’s role in the growing life sciences sector.
The Central SC Alliance represents eight counties: Calhoun, Clarendon, Fairfield, Kershaw, Lexington, Newberry, Orangeburg and Richland, as well as the state capital of Columbia.
To download the full Central South Carolina life sciences study, visit https://www.centralsc.org/target-industries/life-sciences-medical-supplies
###
About Central SC Alliance
The Central SC Alliance (CSCA) is a full-service professional economic development organization, founded in 1994 as a 501(c)(3) not-for-profit, public/private partnership, engaged in the recruitment of capital investment and jobs to the Central Region of South Carolina. Since inception, CSCA and its partners and allies, have attracted $24 billion in capital investment and over 89,000 new jobs to the Central Region of South Carolina.
CSCA represents the City of Columbia and the eight counties: Calhoun, Clarendon, Fairfield, Kershaw, Lexington, Newberry, Orangeburg and Richland.
To learn more, visit centralsc.org and connect with them through
LinkedIn, Facebook, and Instagram.
Media Contact:
Melissa Collins
Director of Marketing
Central SC Alliance
(803) 403-7315
mcolllins@centralsc.org
- Uncategorized
Greenwood Genetic Center Researcher Receives $1.4 Million NIH Grant to Study Metabolism and Glycosylation in Rare Genetic Diseases
Greenwood Genetic Center Researcher Receives $1.4 Million NIH Grant to Study Metabolism and Glycosylation in Rare Genetic Diseases
GREENWOOD, S.C. (October 2026) – Heather Flanagan-Steet, PhD, Associate Director of Research at the Greenwood Genetic Center (GGC), has received a $1.4 million, five-year Maximizing Investigators’ Research Award (MIRA) R35 grant from the National Institutes of Health’s National Institute of General Medical Sciences. The award will support her research into understanding how metabolism and glycosylation — a process by which cells add sugar chains to proteins and lipids — work together during normal development and disease onset.
Dr. Flanagan-Steet studies multiple metabolic disorders, including the congenital disorders of glycosylation (CDG). The CDGs comprise a group of rare inherited diseases caused by changes in genes involved in glycosylation, which is essential for normal protein or lipid function. When glycosylation is disrupted, it can lead to a wide range of health problems, including unexpected secondary changes in how the body utilizes sugar metabolites.
Nearly 200 inherited disorders involving problems with glycosylation have been identified, but researchers are still working to understand how these conditions cause disease, and treatment options remain limited.
Unlike a traditional grant that supports a specific research project, the MIRA award provides broader, long-term support for Dr. Flanagan-Steet’s evolving research program.
“MIRA awards are given to investigators with a proven track record of research and provide greater flexibility to follow promising discoveries as their work evolves,” said Steve Skinner, MD, President and CEO of GGC. “That flexibility is particularly valuable in rare disease research, where an unexpected finding can open an entirely new avenue of investigation. This award is an important recognition of Dr. Flanagan-Steet’s accomplishments as a scientist and the quality of the research program she has developed.”
Dr. Flanagan-Steet and her team use zebrafish models to study how changes in cellular metabolism and glycosylation contribute to disease. Their research includes several forms of CDG, including PMM2-CDG, the most common form of the disorder.
With the support of the new award, the team will investigate how changes in the basic building blocks needed for glycosylation affect cells and tissues, how those changes can disrupt development, and how they ultimately contribute to disease. By studying several forms of CDG using the same model system, the researchers hope to identify common biological pathways that contribute to disease.
“This funding gives us the opportunity to ask broader questions that address key gaps in our understanding of how metabolism and glycosylation are interconnected, following the science as we make new discoveries,” said Dr. Flanagan-Steet. “Ultimately, we hope our work will lead to a better understanding of these rare diseases and point toward new ways to help patients and families.”
The five-year award represents a significant investment in GGC’s research program and its ongoing commitment to advancing the understanding of rare genetic diseases and developing new approaches to improve the lives of patients and families.
Photo: Heather Flanagan-Steet, PhD in GGC’s Allin Aquaculture Facility
###
- Uncategorized
Better Patient Outcomes Depend on a Strong Life Sciences Ecosystem in South Carolina
During the second game of his 2025 National Hockey League season, goaltender Connor Hellebuyck noticed something was wrong with his knee. An MRI later revealed a torn meniscus and a Baker’s cyst.
Yet, within two weeks, he was back on the ice and on track to compete for Olympic gold with Team USA, thanks in large part to treatment with Arthrex’s NanoNeedle Scope 2.0, an arthroscope that is 60% smaller than traditional technology. The smaller instrument gives surgeons another option for examining and treating joint injuries.

Arthrex, which has operations in Anderson County, develops specialized medical devices used in minimally invasive orthopedic procedures, illustrating how South Carolina’s life sciences industry contributes to patient care.
But innovations like these don’t happen in isolation. Behind the technologies, treatments and services that improve patient care is a network of researchers, entrepreneurs, manufacturers, and health care providers that each contribute different expertise to move medical advances forward.
Across South Carolina, companies, universities and health care systems each play a role in that process. SCbio strengthens connections across that network to help the state’s life sciences industry grow while supporting medical advances.
Emerging + Growth-Stage Companies Help Identify Unmet Needs in Patient Health Outcomes
Some of the most promising advancements in patient care begin with an idea or a problem that needs a better solution.
An entrepreneur may see a gap in how a disease is managed. A researcher may discover a new approach to treating an illness. A medical professional may recognize a problem that existing technology does not adequately address.
South Carolina’s emerging life sciences companies are working to solve challenges like these.
- PulManage: Columbia-based PulManage is developing technology to address the challenges of managing chronic lung diseases between medical appointments. Patients with conditions such as COPD and asthma can experience worsening symptoms that lead to serious, potentially life-threatening emergencies. To help provide a solution, founder and registered respiratory therapist Amanda Clark developed a digital health and remote monitoring platform to help patients and providers track symptoms, manage their conditions and identify early warning signs before they become critical.
- MitoChem Therapeutics: Founded by researchers at the Medical University of South Carolina in Charleston, MitoChem Therapeutics is working to address mitochondrial dysfunction, which contributes to neurodegenerative, aging-related and rare diseases. Recognizing the need for treatments that target this underlying cellular problem, the company is developing small-molecule therapies designed to protect and restore mitochondrial function, to address disease at its source.
- ElectroWire Medical: Lexington-based ElectroWire Medical is developing technology to make minimally invasive heart procedures safer and more precise. The company focuses on transseptal access, a procedure that requires physicians to create a small opening between the heart’s upper chambers to reach areas needed for specific cardiac treatments. The team developed its LightningWire Transseptal Puncture System to improve this process using an electrosurgical guidewire-based approach. The technology was recently used in its first clinical cases at Spartanburg Medical Center.
These companies are part of a growing group of emerging and growth-stage businesses in South Carolina, some of which are building on research that begins at the state’s universities.


But bringing those ideas to patients takes resources, expertise and relationships to move the work forward. SCbio brings these innovations to the global stage through its exhibition at the BIO International Convention, helping emerging companies build business opportunities and market their treatments and technologies to industry professionals. The association also helps connect emerging companies with the opportunities and resources they need to advance their work and bring innovations to the patients who need them.
South Carolina Universities Advance Research and Patient Care
Universities across South Carolina are also advancing patient care through investments in research facilities, new technologies and infrastructure that support medical discovery and improve the way patients receive care.
In Columbia, the University of South Carolina recently opened a 65,000-square-foot Brain Health Center in collaboration with Prisma Health. The university is also developing the state’s first standalone Neurological Hospital and Rehabilitation Center, a $350 million project. The Brain Health Center features South Carolina’s only patient-care 7-Tesla MRI scanner, which allows researchers to see brain structure and function with much greater detail and clarity than conventional 3-Tesla scanners.

In Charleston, MUSC is developing a new Comprehensive Cancer Hospital that will build on the expertise of its Hollings Cancer Center, the state’s only National Cancer Institute-designated cancer center. The new facility will bring more specialized care, research and innovation to patients in one place.
In the Upstate, Clemson University, in partnership with MUSC Health and Prisma Health, broke ground on a new 90,000-square-foot, three-story medical and research facility on its main campus to advance patient and student care. Once completed, the complex will provide a comprehensive approach to health and well-being while advancing academic and research relationships.
These investments expand South Carolina’s research capabilities and create opportunities for universities to collaborate with life sciences companies on new technologies, treatments and approaches to patient care.
SCbio helps strengthen those connections by bringing universities and industry partners together to share expertise and advance innovations that can ultimately benefit patients.
Established Life Sciences Organizations Bring Medical Innovations to Patients
As emerging companies and South Carolina universities work to identify and provide new ways to deliver innovative care to patients, established life sciences organizations help develop, produce and deliver solutions at scale.
To do that, the 350 established life sciences organizations in South Carolina are working across diagnostics, pharmaceuticals, medical devices and materials to bring innovative products and solutions to patients worldwide.
One example is the Greenwood Genetic Center (GGC), which provides clinical genetic services, counseling and specialized care in the Upstate. GGC helped a patient, Michael Thames, who lived with an incorrect diagnosis for eight years while his symptoms steadily progressed. After consulting with GGC, his care team identified that he actually had Pompe disease, a rare, treatable genetic condition. GGC provided him with an accurate diagnosis, proper care and renewed hope.
Other examples include BD in Sumter, which develops medical devices, medication-dispensing systems, lab equipment and other technologies used in hospitals nationwide. Zeus also contributes to patient care by supplying polymer tubing, catheter components and other equipment worldwide. Both companies have sites and manufacturing facilities right here in South Carolina.
Other established organizations within the state, including PAI Pharma, Poly-Med, Rhythmlink International, Ritedose, SHL Medical and many others, all represent different parts of the medical product and technology landscape. Their contributions vary, but each company has a distinct way of showing how the products, materials and technologies developed within South Carolina’s life sciences ecosystem all relate back to the bigger mission: supporting better patient outcomes and advancing health care.
Beyond developing and manufacturing medical products, established life sciences organizations also rely on relationships with health care providers to understand how their technologies are used and where opportunities for improvement exist.
SCbio helps companies connect across this network, bringing together manufacturers, researchers and health care organizations whose combined expertise can help advance patient care.
Hospitals Bring the Innovation Directly to Patients
After research is conducted in universities and startup companies, the infrastructure and technology are built, and the products and solutions are manufactured at scale, hospitals can then deliver the solutions directly to patients.
Whether it’s a surgeon using Arthrex’s NanoNeedle 2.0 or a care team deploying a BD infusion pump to deliver critical medications, every piece of technology plays a vital role in the patient journey.
Health systems also bring an important perspective to the broader ecosystem and help shape future innovation. Because clinicians see firsthand the challenges patients face, they can help identify needs that researchers and companies address.
That’s exactly why hospitals like Bon Secours, MUSC Health, Prisma Health, Novant Health and Roper St. Francis Healthcare are a part of the ecosystem. When health care providers, researchers, and industry partners collaborate, they create more opportunities to connect innovation with the realities of patient care.
Better Patient Outcomes Are a Shared Effort Across South Carolina’s Life Sciences Ecosystem
When it comes to improving patients’ lives, every person and organization in South Carolina’s life sciences ecosystem plays a role.
Emerging companies help identify unmet needs, universities advance research and discovery, established organizations develop the solutions and health systems deliver them to patients.
SCbio supports that environment by connecting these institutions, strengthening industry relationships and helping companies find opportunities to grow.
As the ecosystem continues to expand, its impact will be measured not only by the innovations created here, the companies moving to the state, or the economic advancements, but also by how those advances improve patients’ lives.